You've reached the limit for free Overall Ranking scores. For more information, request a demo.
See CSRHub in Action
You have a total of 10 free searches available.
| Low 0-29 | 30-39 | 40-49 | 50-59 | 60-79 | 80-100 High |
Zafgen, Inc. is a biopharmaceutical company engaged in improving the health and well-being of patients affected by obesity. The Company’s product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including obesity and hyperphagia in Prader-Willi syndrome(PWS) patients, hypothalamic injury-associated obesity including craniopharyngioma-associated obesity, and severe obesity in the general population.
Changed name to Larimar Therapeutics Inc from Zafgen Inc, 12/18/2019.
| Ticker: | LRMR |
| ISIN: | US5171251003 |
| Address: |
175 Portland St Fl 4 |
| Boston, MA, 19004, USA | |
| Website: | Larimar Therapeutics Inc |
| Phone #: | 844-511-9056 |
| ESG Web Area: | Subscribers Only ? |
| Industry: | Biotechnology |
We considered many names for our site—in fact we spent our first year and a half under a different name—EkoHub. We liked “Eko” — coming from the Greek word Oikos, related to economy, ecology, and “home” or social concerns. From the beginning, we believed the word “Hub” reflected our desire to be at the center of the sustainability area, providing knowledge, harmony, and consensus among the hundreds of experts judging the ESG performance of companies.